Pre-Research Assessment: Complete medical history and physical review Baseline blood glucose and HbA1c Liver function tests (ALT, AST, bilirubin) Renal function tests (creatinine, BUN, eGFR) Complete blood count Lipid panel IGF-1 and IGFBP-3 levels Thyroid function tests Screening for contraindications During Research Tracking: Regular blood glucose tracking (frequency based on dose and risk factors) Periodic assessment of liver and renal function Tracking for signs of fluid retention Assessment of injection sites Records of any adverse findings Regular evaluation of research parameters Post-Research Assessment: Repeat baseline laboratory tests Evaluation of any persistent effects Assessment of research outcomes Planning of appropriate follow-up Managing Adverse Observations Research protocols should include plans for managing possible adverse findings
The convergence of these lines of research led to what we now know as GLP-1 receptor agonist therapies
[DOI] [Google Scholar] 105.Schne F., Tischendorf F., Leiterer M., Hartung H., Bargholz J
Oral tablets do not require the use of needles are typically taken daily can result in side effects such as nausea, vomiting, constipation, and abdominal pain must be taken on an empty stomach first thing in the morning, without eating for 30 minutes afterward Injections require the use of needles are typically taken once per week may cause side effects such as injection site reactions but may also cause nausea, vomiting, constipation, and abdominal pain can be taken regardless of whether you consume food or liquid beforehand or afterward You can inject semaglutide into your upper arm, thigh, or stomach
Phase II trials in healthy volunteers used 0.16 mg/kg subcutaneous injections with dose-dependent skin darkening (Barnetson et al., 2006)
